



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/714,449	11/16/2000	Gabriel Vogeli	00237.US1	5102

26657 7590 03/15/2002

WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP

[REDACTED] EXAMINER

ATTENTION: SUZANNE E. MILLER ESQ.
ONE LIBERTY PLACE, 46TH FLOOR
PHILADELPHIA, PA 19103

MURPHY, JOSEPH F

ART UNIT	PAPER NUMBER
1646	[REDACTED]

DATE MAILED: 03/15/2002

13

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/714,449	VOGELI ET AL.
Examiner	Art Unit	
Joseph F Murphy	1646	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 16 November 2000.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-97 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-97 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____ .
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ . |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ . | 6) <input type="checkbox"/> Other: _____ . |

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I-XLVIII.Claims 1-35, 77, 80-85, 96 drawn to an isolated nucleic acid, a vector a host cell, and a method of producing the encoded polypeptide, comprising ONE of the following a nucleic acid sequence as set forth in the odd numbered sequences between 1-93 and 185, classified in class 435, subclass 69.1.

XLIX-XCVII.Claims 36-43, 97 drawn to an isolated polypeptide with the amino acid sequence as set forth in the even numbered sequences of ONE of the following: SEQ ID NO: 2-94, 186, classified in class 530, subclass 350.

XCVIII-CXLVI.Claims 44-46, drawn to an antibody which binds to an amino acid sequence as set forth in the even numbered sequences of ONE of the following: SEQ ID NO: 2-94, 186, classified in class 530, subclass 387.1.

CXLVII-CXCV.Claim 47, drawn to a method of inducing an immune response in an animal by administration of an isolated polypeptide with the amino acid sequence as set forth in the even numbered sequences of ONE of the following: SEQ ID NO: 2-94, 186, classified in class 514, subclass 2.

CXCVI-CCXLIV.Claims 48-52, 57-61, 86-90, drawn to a method for identifying a compound which binds an isolated polypeptide with the amino acid sequence as set forth in the even numbered sequences of ONE of the following: SEQ ID NO: 2-94, 186, classified in class 435, subclass 7.2.

CCVL-CCXCIII. Claims 53, 62, drawn to a compound which binds an isolated polypeptide with the amino acid sequence as set forth in the even numbered sequences of ONE of the following: SEQ ID NO: 2-94, 186, classified in class 530, subclass 300.

CCXCIV-CCCXLII. Claims 54-55, drawn to a method for identifying a compound which binds a nucleic acid molecule comprising ONE of the following: a nucleic acid sequence as set forth in the odd numbered sequences between 1-93 and 185, classified in class 435, subclass 6.

CCCXLIII-CCCXCI. Claim 56, drawn to a compound which binds a nucleic acid molecule comprising ONE of the following: a nucleic acid sequence as set forth in the odd numbered sequences between 1-93 and 185, classified in class 530, subclass 388.22.

CCCXCII-CDXL. Claims 63-76, 78-79 drawn to a method of identifying a homolog of a nucleic acid sequence as set forth in the odd numbered sequences between 1-93 and 185, classified in class 435, subclass 6.

CDXLI-CDLXXXIX. Claims 91-95, drawn to a method of isolating a G protein by contacting a sample with the amino acid sequence as set forth in the even numbered sequences of ONE of the following: SEQ ID NO: 2-94, 186, classified in class 530, subclass 412.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-XLVIII, XLIX-XCVII, XCVIII-CXLVI, CCVL-CCXCIII, CCCXLIII-CCCXCI are independent and distinct, each from the other, because they are products which

Art Unit: 1646

possess characteristic differences in structure and function, and each has an independent utility, that is distinct for each invention which cannot be exchanged.

Inventions CXLVII-CXCV, CXCVI-CCXLIV, CCXCIV-CCCXLII, CCCXCII-CDXL, CDXLI-CDLXXXIX are independent and distinct, each from the other, because the methods are practiced with materially different starting materials, have materially different process steps, and are for materially different purposes.

Inventions I-XLVIII are related as product and process of use to inventions CCXCIV-CCCXLII, CCCXCII-CDXL. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the nucleic acids of inventions I-XLVIII can be used for the production of polypeptide.

Inventions XLIX-XCVII are related as product and process of use to inventions CXLVII-CXCV, CXCVI-CCXLIV. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polypeptides of inventions XLIX-XCVII can be used for the production of antibody.

Inventions XCVIII-CXLVI are unrelated to inventions CXLVII-CXCV, CXCVI-CCXLIV, CCXCIV-CCCXLII, CCCXCII-CDXL, CDXLI-CDLXXXIX. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have

different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not disclosed as capable of use together.

Inventions CCVL-CCXCIII and CXCVI-CCXLIV are independent and distinct, each from the other, because the structure of the compound is independent of the means of identifying it, especially as the functional assay of groups CXCVI-CCXLIV would reasonably be expected to identify numerous compounds having distinct structures and functions.

Inventions CCCXLIII-CCCXCI and CCXCIV-CCCXLII are independent and distinct, each from the other, because the structure of the compound is independent of the means of identifying it, especially as the functional assay of groups CCCXLIII-CCCXCI would reasonably be expected to identify numerous compounds having distinct structures and functions.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).


Art Unit: 1646

Advisory Information


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph F. Murphy whose telephone number is 703-305-7245. The examiner can normally be reached on M-F 7:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on 703-308-6564. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-308-0294 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.



Joseph F. Murphy, Ph. D.
Patent Examiner
Art Unit 1646
March 12, 2002



DAVID S. ROMEO
PRIMARY EXAMINER